YHB Investment Advisors Inc. lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,969 shares of the biopharmaceutical company’s stock after selling 1,041 shares during the quarter. YHB Investment Advisors Inc.’s holdings in Gilead Sciences were worth $1,932,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Welch Investments LLC purchased a new position in Gilead Sciences during the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new position in Gilead Sciences during the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new position in Gilead Sciences during the 3rd quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Gilead Sciences during the 2nd quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management boosted its holdings in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $80.70 on Friday. The company has a current ratio of 3.55, a quick ratio of 3.48 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $105,390.00, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.83%. Gilead Sciences’s payout ratio is 59.77%.
A number of equities analysts have recently commented on GILD shares. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets dropped their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, October 27th. Mizuho set a $77.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, Argus cut Gilead Sciences from a “buy” rating to a “hold” rating and lifted their target price for the stock from $73.25 to $73.77 in a report on Monday, November 13th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $87.04.
In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the completion of the sale, the insider now directly owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the sale, the insider now directly owns 3,070,099 shares of the company’s stock, valued at $230,196,023.02. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 418,333 shares of company stock valued at $32,742,108. 1.30% of the stock is currently owned by corporate insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.